RIPK3 and neoplasm: In this study, ectopic activation of RIPK3 promoted tumor antigen loading by tumor APCs (antigen presenting cells) associated with enhanced CD8+ T cell-mediated anti-tumor responses, which synergized with α-PD-1 co-administration to promote tumor clearance.